FNBT
AEGR

FineMark National Bank & Trust’s Aegerion Pharmaceuticals AEGR Stock Holding History

FineMark National Bank & Trust’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-17
Closed -$1K – 1450
2014
Q2 		$1K Hold
17
– – ﹤0.01% 1381
2014
Q1 		$1K Hold
17
– – ﹤0.01% 1395
2013
Q4 		$1K Buy
+17
New +$1.3K ﹤0.01% 1453

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FineMark National Bank & Trust's AEGR Position: Q3 2014 in Review

FineMark National Bank & Trust sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2014, closing a stake of 17 shares — an estimated $1K sold.

FineMark National Bank & Trust first reported a position in AEGR in Q4 2013 and held it in 3 quarters. The position peaked at $1K in Q2 2014. 131 funds tracked by Wall St. Rank hold AEGR as of Q3 2014.

  • FineMark National Bank & Trust reported no remaining Aegerion Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • FineMark National Bank & Trust sold 17 Aegerion Pharmaceuticals shares in Q3 2014, an estimated $1K.
  • FineMark National Bank & Trust first reported a position in Aegerion Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • FineMark National Bank & Trust's Aegerion Pharmaceuticals position peaked at $1K in Q2 2014.
  • 131 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2014.

Based on FineMark National Bank & Trust's 13F filing for Q3 2014, filed 13 Nov 2014.